Eidos Therapeutics, Inc.
(NASDAQ GS: EIDX)
Attention investors who purchased shares of Eidos Therapeutics, Inc. before October 5, 2020:
Rigrodsky & Long is investigating potential claims against the board of directors of Eidos Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by BridgeBio Pharma, Inc.
Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO). Under the terms of the agreement, Eidos’ shareholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share.
You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or firstname.lastname@example.org.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.